# Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

> **NCT06673069** · PHASE1 · TERMINATED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Alzheimer Disease
- Down Syndrome

## Interventions

- **DRUG:** ION269

## Key facts

- **NCT ID:** NCT06673069
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-20
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study early. Decision not based on safety concerns.
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673069, "Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06673069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*